Ablynx data on RA candidate boosts partnering
This article was originally published in Scrip
Executive Summary
The awaited 24-week final analysis of the Phase II study of Ablynx's IL-6 receptor inhibitor nanobody ALX-0061, for rheumatoid arthritis has confirmed the interim proof-of-concept data released last October (scripintelligence.com, 4 October 2012). The data will add fuel to Ablynx's partnering discussions for the program.